ICE® constructs targeting the CD16A NK cell receptor induced a more extensive EpCAM+ tumor cell destruction than the EpCAM/NKp46 ICE® (Table 7), despite a lower binding affinity to CD16A (Figure 3 and Table 4). The gene discussed is FCGR3A; the disease is neoplasm.